{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zimberelimab", "query": { "intervention": "Zimberelimab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zimberelimab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T03:56:35.290Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05886634", "title": "A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dedifferentiated Liposarcoma", "Soft Tissue Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma", "Recurrent Dedifferentiated Liposarcoma", "Unresectable Dedifferentiated Liposarcoma", "Metastatic Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-05-23", "completion_date": "2027-05-23", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05886634" }, { "nct_id": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Merkel Cell Carcinoma", "GastroEsophageal Cancer", "Renal Cell Carcinoma", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-07-24", "completion_date": "2021-09-03", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03629756" }, { "nct_id": "NCT05891171", "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Malignancies", "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer (GEJ)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-Small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Renal Cell Carcinoma (RCC)", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "AB598", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-10-13", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lake City", "state": "Florida" }, { "city": "Hinsdale", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891171" }, { "nct_id": "NCT04747470", "title": "Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "GS-3583", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-03-25", "completion_date": "2022-11-07", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 4, "location_summary": "Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04747470" }, { "nct_id": "NCT05724563", "title": "Domvanalimab and Zimberelimab in Advanced Liver Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatobiliary Cancer", "Liver Cancer", "Cholangiocarcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2023-06-12", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05724563" }, { "nct_id": "NCT05568095", "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Upper Gastrointestinal Tract Adenocarcinoma" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1040, "start_date": "2022-11-21", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 31, "location_summary": "Los Angeles, California • Orange, California • Santa Monica, California + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05568095" }, { "nct_id": "NCT05130177", "title": "Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-16", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130177" }, { "nct_id": "NCT07619313", "title": "AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Locally Advanced Cholangiocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Cholangiocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Ligritinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2026-05-29", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619313" }, { "nct_id": "NCT05335941", "title": "A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-06-13", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05335941" }, { "nct_id": "NCT05024097", "title": "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Etrumadenant (AB928)", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Zimberelimab (AB122)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2022-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-03T03:56:35.290Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024097" } ] }